NEW YORK (GenomeWeb) – Ag-bio organizations Cellectis Plant Sciences and the Two Blades Foundation announced that they have signed a cross-licensing agreement for their respective TAL effector nuclease gene-editing technologies.

Under the deal, Two Blades has received a license to Cellectis' TALEN technology for non-profit uses, including its efforts to support subsistence farming, as well as certain commercial applications related to its ongoing disease-resistance programs.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.